Physician profile
John Efthyvoulidis
NPI 1194352815
$2,498.95
in general payments reported to CMS, 2019-2025
26 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $206 · 2023: $292 · 2024: $776 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.84 | 2022-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $264.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $258.96 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $194.28 | 2023-2025 | |
| Alk-Abello, INC | $181.33 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Kowa Pharmaceuticals America, INC. | $150.87 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $142.11 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $126.61 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $94.46 | 2021 | |
| Genzyme Corporation | $93.69 | 2022 | |
| Glaxosmithkline, LLC. | $89.98 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.78 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $82.58 | 2021-2025 | Vpriv |
| Novo Nordisk INC | $74.54 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $46.95 | 2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $44.83 | 2024-2025 | Injectafer |
| Amgen INC. | $43.84 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $39.54 | 2023-2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $35.19 | 2024-2025 | Opsumit, Uptravi |
| Dexcom, INC. | $33.48 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $24.05 | 2025 | Nexplanon |
| Cepheid | $22.03 | 2025 | Genexpert |
| Ethicon INC. | $21.94 | 2025 | Monarch Platform |
| Ani Pharmaceuticals, INC. | $19.67 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $17.35 | 2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $17.26 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Efthyvoulidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.